Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of CnU Cap. 500 mg in Patients With Biliary Dyspepsia [Phase 4]

View source ↗

Summary

This is a Phase 4 clinical trial evaluating the efficacy and safety of CnU Cap. 500 mg in patients with biliary dyspepsia, sponsored by Myungmoon Pharma Co. Ltd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Dyspepsia

Drugs mentioned

• CnU Cap. 500 mg

Snippet

Sponsor: Myungmoon Pharma. Co. Ltd. | Conditions: Biliary Dyspepsia | Phase 4 | Status: RECRUITING